GRI News & Events

GRI Bio Inc trading halted, volatility trading pause

GRI Bio announced additional "positive" data from its recently completed Phase 2a clinical study of GRI-0621 in Idiopathic Pulmonary Fibrosis, IPF, further strengthening potential clinical proof-of-concept and reinforcing the therapeutic differentiation of GRI-0621. Newly reported RNA-sequencing differential gene expression data demonstrate that treatment with GRI-0621 resulted in significant improvement across genes associated with lung injury, myofibroblast activation, extracellular matrix deposition, fibrosis progression, and alveolar basement membrane and epithelial repair compared to placebo. These findings represent a potential independent validation of previously reported biomarker, functional and clinical signals from the Phase 2a study.

GRI Bio announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12,528,775, providing robust new intellectual property protection for novel compound compositions central to the Company's platform of immunomodulators. The newly issued patent includes composition-of-matter claims covering a distinct class of proprietary compounds defined by linked molecular structures that form pyrrolidine, piperidine, or azepane ring systems. These specific molecular configurations represent a key structural advancement and are separate and distinct from patents previously issued to the Company, further strengthening the durability of GRI Bio's intellectual property estate.